|Bid||17.01 x 900|
|Ask||17.10 x 1200|
|Day's Range||17.02 - 17.36|
|52 Week Range||14.91 - 26.25|
|Beta (3Y Monthly)||1.06|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The NASH liver disease treatment market is growing with biotech companies like Intercept and Genfit in late-stage tests. Experts say the market for a successful drug could be worth billions.
For many, the main point of investing is to generate higher returns than the overall market. But in any portfolio...
A look at the shareholders of Genfit SA (EPA:GNFT) can tell us which group is most powerful. Institutions often own...
Insider Monkey has processed numerous 13F filings of hedge funds and successful investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...
Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. Under the terms of the agreement, Terns acquires the exclusive right to develop, register, and market elafibranor for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) in Greater China (mainland China, Hong Kong, Macau, and Taiwan).
ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) shares were rallying Monday on positive news related to its non-alcoholic steatohepatitis, or NASH, drug. ContraVir, which came under pressure Friday following ...
Investors seeking to find the next great pharmaceutical company may want to concentrate on emerging biopharma. Warning! GuruFocus has detected 5 Warning Signs with GNFT. The company's focus is liver disease.
GENFIT S.A. (GNFT), a late-stage clinical biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, rang the Nasdaq MarketSite bell in Times Square today in celebration of its initial public offering on The Nasdaq Stock Market. GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Genfit S.A. (GNFT) will issue 5 million shares at $26.33 each Wednesday ...